A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Part of paid clinical trials in Lenexa, Kansas.

Sponsor
Novo Nordisk A/S
Study ID
NCT07767175
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • NNC0721-8060 — DRUG
    NNC0721-8060 will be administered subcutaneously.
  • Semaglutide — DRUG
    Semaglutide will be administered subcutaneously.
  • Placebo — DRUG
    Placebo will be administered subcutaneously.

Study Details

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Key Dates

First listed
Aug 17, 2026
Start date
Aug 12, 2026
Status verified
Aug 2026
Primary completion
Sep 23, 2027
Completion
Sep 23, 2027

Study Design

Enrollment
142 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0721-8060
    Participants will receive subcutaneous injection of NNC0721-8060.
  • Active Comparator: Semaglutide
    Participants will receive subcutaneous injection of semaglutide.
  • Placebo Comparator: Placebo
    Participants will receive subcutaneous injection of placebo.

Primary Outcome Measure

Part A: Number of treatment emergent adverse events (TEAE) [ Time Frame: From Day 1 to Day 36 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
ICON Early Phase Services, LLCLenexaKansas66219-
ICONSan AntonioTexas78209-

Find similar trials in Lenexa, KS

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
ICON Early Phase Services, LLC· Lenexa, KSICON· San Antonio, TX

Related Studies